Last reviewed · How we verify

Elspar — Competitive Intelligence Brief

Elspar (ASPARAGINASE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Asparagine-specific Enzyme [EPC]. Area: Oncology.

marketed Asparagine-specific Enzyme [EPC] L-asparagine Oncology Enzyme Live · refreshed every 30 min

Target snapshot

Elspar (ASPARAGINASE) — Merck & Co.. RYLAZE kills leukemic cells by depleting plasma asparagine, which they need for survival.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Elspar TARGET ASPARAGINASE Merck & Co. marketed Asparagine-specific Enzyme [EPC] L-asparagine 1994-01-01
Asparlas calaspargase Pfizer marketed Asparagine-specific Enzyme [EPC] L-asparagine 2018-01-01
ASPARAGINASE ERWINIA CHRYSANTHEMI ASPARAGINASE ERWINIA CHRYSANTHEMI marketed Asparagine-specific Enzyme [EPC] L-asparagine 2011-01-01
Asparlas CALASPARGASE PEGOL Servier Pharma Llc marketed Asparagine-specific Enzyme [EPC] 2018-01-01
PEGASPARGASE PEGASPARGASE marketed Asparagine-specific Enzyme [EPC] 1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Asparagine-specific Enzyme [EPC] class)

  1. · 2 drugs in this class
  2. Merck & Co. · 1 drug in this class
  3. Pfizer · 1 drug in this class
  4. Servier Pharma Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elspar — Competitive Intelligence Brief. https://druglandscape.com/ci/asparaginase. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: